FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904295020> ?p ?o ?g. }

• W2904295020 endingPage "390" @default.
• W2904295020 startingPage "382" @default.
• W2904295020 abstract "Glutamate is the principal excitatory neurotransmitter in the brain and is at the base of a wide variety of neuropathologies, including epilepsy, autism, Fragile X, and obsessive compulsive disorder. Glutamate has also become the target for novel drugs in treatment and in fundamental research settings. However, much remains unknown on the working mechanisms of these drugs and the effects of chronic administration on the glutamatergic system. This study investigated the chronic effects of two glutamate-modulating drugs with imaging techniques to further clarify their working mechanisms for future research opportunities. Animals were exposed to saline (1 ml/kg), (5<i>S</i>,10<i>R</i>)-(+)-5-Methyl-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>]cyclohepten-5,10-imine (MK-801) (0.3 mg/kg), or ebselen (10 mg/kg) for 7 consecutive days. At the sixth injection, animals underwent a positron emission tomography (PET)/computed tomography (CT) with (3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-<i>O</i>-11C-methyl-oxime) (ABP-688) to visualize the metabotropic G protein–coupled glutamate receptor 5 (mGluR5). After the seventh injection, animals underwent a magnetic resonance spectroscopy (MRS) scan to visualize glutamate and glutamine content. Afterward, results were verified by mGluR5 immunohistochemistry (IHC). PET/CT analysis revealed that animals receiving chronic MK-801 or ebselen had a significant (<i>P</i> < 0.05) higher binding potential (2.90 ± 0.47 and 2.87 ± 0.46, respectively) when compared with saline (1.97 ± 0.39) in the caudate putamen. This was confirmed by mGluR5 IHC, with 60.83% ± 6.30% of the area being highlighted for ebselen and 57.14% ± 9.23% for MK-801 versus 50.21% ± 5.71% for the saline group. MRS displayed significant changes on the glutamine level when comparing chronic ebselen (2.20 ± 0.40 <i>µ</i>mol/g) to control (2.72 ± 0.34 <i>µ</i>mol/g). Therefore, although no direct effects on glutamate were visualized, the changes in glutamine suggest changes in the total glutamate-glutamine pool. This highlights the potential of both drugs to modulate glutamatergic pathologies." @default.
• W2904295020 created "2018-12-22" @default.
• W2904295020 creator A5003193683 @default.
• W2904295020 creator A5007699786 @default.
• W2904295020 creator A5044437921 @default.
• W2904295020 creator A5050774304 @default.
• W2904295020 creator A5054694345 @default.
• W2904295020 creator A5083236320 @default.
• W2904295020 date "2018-12-14" @default.
• W2904295020 modified "2023-09-25" @default.
• W2904295020 title "In Vivo Preclinical Molecular Imaging of Repeated Exposure to an N-methyl-d-aspartate Antagonist and a Glutaminase Inhibitor as Potential Glutamatergic Modulators" @default.
• W2904295020 cites W1254326893 @default.
• W2904295020 cites W1730237872 @default.
• W2904295020 cites W1771209779 @default.
• W2904295020 cites W1852488041 @default.
• W2904295020 cites W1977083983 @default.
• W2904295020 cites W1982210031 @default.
• W2904295020 cites W1983365529 @default.
• W2904295020 cites W1986908397 @default.
• W2904295020 cites W1990484506 @default.
• W2904295020 cites W1992379299 @default.
• W2904295020 cites W1992483383 @default.
• W2904295020 cites W1998622616 @default.
• W2904295020 cites W2000519244 @default.
• W2904295020 cites W2004422759 @default.
• W2904295020 cites W2008502131 @default.
• W2904295020 cites W2008639041 @default.
• W2904295020 cites W2017032137 @default.
• W2904295020 cites W2025977308 @default.
• W2904295020 cites W2032430743 @default.
• W2904295020 cites W2047737185 @default.
• W2904295020 cites W2049983193 @default.
• W2904295020 cites W2051107661 @default.
• W2904295020 cites W2066758197 @default.
• W2904295020 cites W2072468049 @default.
• W2904295020 cites W2078051262 @default.
• W2904295020 cites W2080914771 @default.
• W2904295020 cites W2084290400 @default.
• W2904295020 cites W2099486389 @default.
• W2904295020 cites W2109125813 @default.
• W2904295020 cites W2117671988 @default.
• W2904295020 cites W2127777921 @default.
• W2904295020 cites W2137060989 @default.
• W2904295020 cites W2138631087 @default.
• W2904295020 cites W2139374843 @default.
• W2904295020 cites W2146699327 @default.
• W2904295020 cites W2146729652 @default.
• W2904295020 cites W2154108863 @default.
• W2904295020 cites W2155881068 @default.
• W2904295020 cites W2156342513 @default.
• W2904295020 cites W2162893002 @default.
• W2904295020 cites W2162978906 @default.
• W2904295020 cites W2168367599 @default.
• W2904295020 cites W2265192859 @default.
• W2904295020 cites W2315263438 @default.
• W2904295020 cites W2385482058 @default.
• W2904295020 cites W2406653178 @default.
• W2904295020 cites W2600735357 @default.
• W2904295020 cites W2771177178 @default.
• W2904295020 cites W2793468531 @default.
• W2904295020 cites W3026829963 @default.
• W2904295020 cites W627490077 @default.
• W2904295020 doi "https://doi.org/10.1124/jpet.118.252635" @default.
• W2904295020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30552293" @default.
• W2904295020 hasPublicationYear "2018" @default.
• W2904295020 type Work @default.
• W2904295020 sameAs 2904295020 @default.
• W2904295020 citedByCount "6" @default.
• W2904295020 countsByYear W29042950202018 @default.
• W2904295020 countsByYear W29042950202019 @default.
• W2904295020 countsByYear W29042950202020 @default.
• W2904295020 countsByYear W29042950202022 @default.
• W2904295020 countsByYear W29042950202023 @default.
• W2904295020 crossrefType "journal-article" @default.
• W2904295020 hasAuthorship W2904295020A5003193683 @default.
• W2904295020 hasAuthorship W2904295020A5007699786 @default.
• W2904295020 hasAuthorship W2904295020A5044437921 @default.
• W2904295020 hasAuthorship W2904295020A5050774304 @default.
• W2904295020 hasAuthorship W2904295020A5054694345 @default.
• W2904295020 hasAuthorship W2904295020A5083236320 @default.
• W2904295020 hasBestOaLocation W29042950201 @default.
• W2904295020 hasConcept C126322002 @default.
• W2904295020 hasConcept C134018914 @default.
• W2904295020 hasConcept C170493617 @default.
• W2904295020 hasConcept C185592680 @default.
• W2904295020 hasConcept C2776885963 @default.
• W2904295020 hasConcept C2780648746 @default.
• W2904295020 hasConcept C41653306 @default.
• W2904295020 hasConcept C49051014 @default.
• W2904295020 hasConcept C61174792 @default.
• W2904295020 hasConcept C71924100 @default.
• W2904295020 hasConcept C98274493 @default.
• W2904295020 hasConceptScore W2904295020C126322002 @default.
• W2904295020 hasConceptScore W2904295020C134018914 @default.
• W2904295020 hasConceptScore W2904295020C170493617 @default.
• W2904295020 hasConceptScore W2904295020C185592680 @default.
• W2904295020 hasConceptScore W2904295020C2776885963 @default.
• W2904295020 hasConceptScore W2904295020C2780648746 @default.

• next